Research & Literature

Grey zones in the diagnosis of adult migraine without aura based on the International Classification of Headache Disorders-III beta: exploring the covariates of possible migraine without aura.

Ozge A, Aydinlar E, Tasdelen B

Pain research & management 2015; (20(1)):e1-7.

Variability of the characteristics of a migraine attack within patients.

Viana M, Sances G, Ghiotto N, et al.

Cephalalgia : an international journal of headache 2016; (36(9)):825-30 doi:10.1177/0333102415613612.

Headache and migraine: a leading cause of absenteeism.

Baigi K, Stewart WF

Handbook of clinical neurology 2015; (131()):447-63.

Aerobic Exercise for Reducing Migraine Burden: Mechanisms, Markers, and Models of Change Processes.

Irby MB, Bond DS, Lipton RB, et al.

Headache 2016; (56(2)):357-69 doi:10.1111/head.12738.

Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine.

Guo S, Christensen AF, Liu ML, et al.

Cephalalgia : an international journal of headache 2017; (37(2)):114-124 doi:10.1177/0333102416639512.

Headache, depression and anxiety: associations in the Eurolight project.

Lampl C, Thomas H, Tassorelli C, et al.

The journal of headache and pain 2016; (17()):59 doi:10.1186/s10194-016-0649-2.

Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine.

Guo S, Vollesen ALH, Olesen J, Ashina M

Pain 2016; (157(12)):2773-2781 doi:10.1097/j.pain.0000000000000702.

Risk of medication overuse headache across classes of treatments for acute migraine.

Thorlund K, Sun-Edelstein C, Druyts E, et al.

The journal of headache and pain 2016; (17(1)):107 doi:10.1186/s10194-016-0696-8.

Topiramate in Migraine Prevention: A 2016 Perspective.

Silberstein SD

Headache 2017; (57(1)):165-178 doi:10.1111/head.12997.

Reconsideration of the diagnosis and treatment of childhood migraine: A practical review of clinical experiences.

Saito Y, Yamanaka G, Shimomura H, et al.

Brain & development 2017; (39(5)):386-394 doi:10.1016/j.braindev.2016.11.011.

Treatment Update of Chronic Migraine.

Cho SJ, Song TJ, Chu MK

Current pain and headache reports 2017; (21(6)):26 doi:10.1007/s11916-017-0628-6.

Paranasal Sinus Disease in Children With Headache.

Vieira Neto RJ, Teixeira KCS, Guerreiro MM, Montenegro MA

Journal of child neurology 2017; (32(12)):1014-1017 doi:10.1177/0883073817724696.

Clinical description of attack-related cognitive symptoms in migraine: A systematic review.

Gil-Gouveia R, Martins IP

Cephalalgia : an international journal of headache 2018; (38(7)):1335-1350 doi:10.1177/0333102417728250.

Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs).

Haywood KL, Mars TS, Potter R, et al.

Cephalalgia : an international journal of headache 2018; (38(7)):1374-1386 doi:10.1177/0333102417731348.

Sleep disturbances in tension-type headache and migraine.

Fernández-de-Las-Peñas C, Fernández-Muñoz JJ, Palacios-Ceña M, et al.

Therapeutic advances in neurological disorders 2018; (11()):1756285617745444 doi:10.1177/1756285617745444.

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.

Blumenfeld AM, Stark RJ, Freeman MC, et al.

The journal of headache and pain 2018; (19(1)):13 doi:10.1186/s10194-018-0840-8.

Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.

Negro A, Koverech A, Martelletti P

Journal of pain research 2018; (11()):515-526 doi:10.2147/JPR.S132833.

Nosographic analysis of osmophobia and field testing of diagnostic criteria including osmophobia.

Chalmer MA, Hansen TF, Olesen J

Cephalalgia : an international journal of headache 2019; (39(1)):38-43 doi:10.1177/0333102418771375.

Aura in Cluster Headache: A Cross-Sectional Study.

de Coo IF, Wilbrink LA, Ie GD, et al.

Headache 2018; (58(8)):1203-1210 doi:10.1111/head.13344.

Botulinum toxins for the prevention of migraine in adults.

Herd CP, Tomlinson CL, Rick C, et al.

The Cochrane database of systematic reviews 2018; (6()):CD011616 doi:10.1002/14651858.CD011616.pub2.

Blink Reflex in Episodic and Chronic Migraine.

Polat B, Aysal F, Öztürk M, et al.

Noro psikiyatri arsivi 2018; (55(2)):146-151 doi:10.5152/npa.2017.12753.

The Migraine Premonitory Phase.

Karsan N, Bose P, Goadsby PJ

Continuum (Minneapolis, Minn.) 2018; (24(4, Headache)):996-1008 doi:10.1212/CON.0000000000000624.

Headache in Pregnancy.

Robbins MS

Continuum (Minneapolis, Minn.) 2018; (24(4, Headache)):1092-1107 doi:10.1212/CON.0000000000000642.

Sleep and Migraine: Assessment and Treatment of Comorbid Sleep Disorders.

Rains JC

Headache 2018; (58(7)):1074-1091 doi:10.1111/head.13357.

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.

Bendtsen L, Sacco S, Ashina M, et al.

The journal of headache and pain 2018; (19(1)):91 doi:10.1186/s10194-018-0921-8.

Triggers, Protectors, and Predictors in Episodic Migraine.

Marmura MJ

Current pain and headache reports 2018; (22(12)):81 doi:10.1007/s11916-018-0734-0.

The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice.

Headache 2019; (59(1)):1-18 doi:10.1111/head.13456.

An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.

Ahmed F, Gaul C, García-Moncó JC, et al.

The journal of headache and pain 2019; (20(1)):26 doi:10.1186/s10194-019-0976-1.

Changes of primary headache related white matter lesions in pediatric patients.

Bayram E, Yiş U, Paketçi C, et al.

The Turkish journal of pediatrics 2018; (60(4)):380-384.

CGRP and the Trigeminal System in Migraine.

Iyengar S, Johnson KW, Ossipov MH, Aurora SK

Headache 2019; (59(5)):659-681 doi:10.1111/head.13529.

Secondary Headaches During Pregnancy: When to Worry.

Sandoe CH, Lay C

Current neurology and neuroscience reports 2019; (19(6)):27 doi:10.1007/s11910-019-0944-9.

Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial.

Yarnitsky D, Dodick DW, Grosberg BM, et al.

Headache 2019; (59(8)):1240-1252 doi:10.1111/head.13551.

The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse.

van Hoogstraten WS, MaassenVanDenBrink A

The journal of headache and pain 2019; (20(1)):54 doi:10.1186/s10194-019-1007-y.

Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.

Winner PK, Blumenfeld AM, Eross EJ, et al.

Drug safety 2019; (42(8)):1013-1024 doi:10.1007/s40264-019-00824-3.

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.

Goadsby PJ, Wietecha LA, Dennehy EB, et al.

Brain : a journal of neurology 2019; (142(7)):1894-1904 doi:10.1093/brain/awz134.

Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.

Mathew PG, Klein BC

Headache 2019; (59(8)):1421-1426 doi:10.1111/head.13601.

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Rubio-Beltrán E, Labastida-Ramírez A, Haanes KA, et al.

British journal of pharmacology 2019; (176(24)):4681-4695 doi:10.1111/bph.14832.

A prospective study on osmophobia in migraine versus tension-type headache in a large series of attacks.

Terrin A, Mainardi F, Lisotto C, et al.

Cephalalgia : an international journal of headache 2020; (40(4)):337-346 doi:10.1177/0333102419877661.

Headache in the elderly.

Kaniecki RG, Levin AD

Handbook of clinical neurology 2019; (167()):511-528 doi:10.1016/B978-0-12-804766-8.00028-5.

Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.

Munjal S, Singh P, Reed ML, et al.

Headache 2020; (60(2)):416-429 doi:10.1111/head.13708.

One-Day Acceptance and Commitment Therapy Compared to Support for Depressed Migraine Patients: a Randomized Clinical Trial.

Dindo LN, Recober A, Calarge CA, et al.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2020; (17(2)):743-753 doi:10.1007/s13311-019-00818-0.

Subcutaneous sumatriptan reduces cilostazol induced headache in migraine patients.

Falkenberg K, Bjerg HR, Olesen J

Cephalalgia : an international journal of headache 2020; (40(8)):842-850 doi:10.1177/0333102420915166.

From transformation to chronification of migraine: pathophysiological and clinical aspects.

Torres-Ferrús M, Ursitti F, Alpuente A, et al.

The journal of headache and pain 2020; (21(1)):42 doi:10.1186/s10194-020-01111-8.

Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.

Schoenen J, Manise M, Nonis R, et al.

Revue neurologique 2020; (176(10)):788-803 doi:10.1016/j.neurol.2020.04.027.

Differential medication overuse risk of novel anti-migraine therapeutics.

Saengjaroentham C, Strother LC, Dripps I, et al.

Brain : a journal of neurology 2020; (143(9)):2681-2688 doi:10.1093/brain/awaa211.

Secondary headache attributed to exposure to or overuse of a substance.

Toom K, Braschinsky M, Obermann M, Katsarava Z

Cephalalgia : an international journal of headache 2021; (41(4)):443-452 doi:10.1177/0333102420942238.

Headaches during pregnancy.

de Gaalon S, Donnet A

Revue neurologique 2021; (177(3)):195-202 doi:10.1016/j.neurol.2020.05.012.

Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.

Alex A, Vaughn C, Rayhill M

Headache 2020; (60(10)):2454-2462 doi:10.1111/head.13956.

Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.

Joyner KR, Morgan KW

The Annals of pharmacotherapy 2021; (55(6)):745-759 doi:10.1177/1060028020963574.

OnabotulinumtoxinA injection in the treatment of chronic migraine.

Wang YF

Progress in brain research 2020; (255()):171-206 doi:10.1016/bs.pbr.2020.05.013.

Are some patient-perceived migraine triggers simply early manifestations of the attack?

Karsan N, Bose P, Newman J, Goadsby PJ

Journal of neurology 2021; (268(5)):1885-1893 doi:10.1007/s00415-020-10344-1.

The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.

Lipton RB, Seng EK, Chu MK, et al.

Headache 2020; (60(8)):1683-1696 doi:10.1111/head.13914.

Ubrogepant to Treat Acute Migraine in Adults.

Edinoff AN, Casey CA, Colon MA, et al.

Neurology international 2021; (13(1)):32-45 doi:10.3390/neurolint13010004.

Premonitory symptoms in migraine from China: A multi-clinic study of 4821 patients.

Wang X, Yin Z, Lian Y, et al.

Cephalalgia : an international journal of headache 2021; (41(9)):991-1003 doi:10.1177/0333102421997850.

Lasmiditan for the acute treatment of migraine.

DeJulio PA, Perese JK, Schuster NM, Oswald JC

Pain management 2021; (11(5)):437-449 doi:10.2217/pmt-2021-0002.

Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis.

VanderPluym JH, Halker Singh RB, Urtecho M, et al.

JAMA 2021; (325(23)):2357-2369 doi:10.1001/jama.2021.7939.

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.

Ailani J, Burch RC, Robbins MS,

Headache 2021; (61(7)):1021-1039 doi:10.1111/head.14153.

Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.

Overeem LH, Raffaelli B, Mecklenburg J, et al.

CNS drugs 2021; (35(8)):805-820 doi:10.1007/s40263-021-00834-9.

Migraine: interactions between brain's trait and state.

Szabo E, Green S, Karunakaran KD, et al.

CNS spectrums 2022; (27(5)):561-569 doi:10.1017/S109285292100064X.

Narrative review of neuroimaging in migraine with aura.

Arca KN, VanderPluym JH, Halker Singh RB

Headache 2021; (61(9)):1324-1333 doi:10.1111/head.14191.

Migraine with aura.

Lucas C

Revue neurologique 2021; (177(7)):779-784 doi:10.1016/j.neurol.2021.07.010.

Aura in trigeminal autonomic cephalalgia is probably mediated by comorbid migraine with aura.

Peng KP, Schellong M, May A

Cephalalgia : an international journal of headache 2022; (42(1)):31-36 doi:10.1177/03331024211030499.

Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits.

Martins-Oliveira M, Tavares I, Goadsby PJ

Brain research 2021; (1770()):147629 doi:10.1016/j.brainres.2021.147629.

Osmophobia in primary headache patients: associated symptoms and response to preventive treatments.

Delussi M, Laporta A, Fraccalvieri I, de Tommaso M

The journal of headache and pain 2021; (22(1)):109 doi:10.1186/s10194-021-01327-2.

Hypothalamic structural integrity and temporal complexity of cortical information processing at rest in migraine without aura patients between attacks.

Porcaro C, Di Renzo A, Tinelli E, et al.

Scientific reports 2021; (11(1)):18701 doi:10.1038/s41598-021-98213-3.

Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles.

Hautakangas H, Winsvold BS, Ruotsalainen SE, et al.

Nature genetics 2022; (54(2)):152-160 doi:10.1038/s41588-021-00990-0.

Behavioral Management of Episodic Migraine: Maintaining a Healthy Consistent Lifestyle.

Seng EK, Gosnell I, Sutton L, Grinberg AS

Current pain and headache reports 2022; (26(3)):247-252 doi:10.1007/s11916-022-01023-z.

The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.

Cohen F, Yuan H, DePoy EMG, Silberstein SD

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2022; (19(3)):922-930 doi:10.1007/s13311-022-01230-x.

An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App).

Casanova A, Vives-Mestres M, Donoghue S, et al.

Headache 2022; (62(10)):1406-1415 doi:10.1111/head.14328.

Neuroimaging of Headache: Indications and Controversies.

Asadollahi S, Yousem DM, Nadgir R

Neurologic clinics 2022; (40(3)):471-489 doi:10.1016/j.ncl.2022.02.001.

Sensitivity of the SNNOOP10 list in the high-risk secondary headache detection.

García-Azorín D, Abelaira-Freire J, González-García N, et al.

Cephalalgia : an international journal of headache 2022; (42(14)):1521-1531 doi:10.1177/03331024221120249.

Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.

De Icco R, Vaghi G, Allena M, et al.

The journal of headache and pain 2022; (23(1)):123 doi:10.1186/s10194-022-01480-2.

Current Perspectives on the Impact of Chronic Migraine on Sleep Quality: A Literature Review.

Saçmacı H, Tanik N, İnan LE

Nature and science of sleep 2022; (14()):1783-1800 doi:10.2147/NSS.S335949.

The role of avoiding known triggers, embracing protectors, and adhering to healthy lifestyle recommendations in migraine prophylaxis: Insights from a prospective cohort of 1125 people with episodic migraine.

Casanova A, Vives-Mestres M, Donoghue S, et al.

Headache 2023; (63(1)):51-61 doi:10.1111/head.14451.

Sex differences in clinical characteristics of migraine and its burden: a population-based study.

Chalmer MA, Kogelman LJA, Callesen I, et al.

European journal of neurology 2023; (30(6)):1774-1784 doi:10.1111/ene.15778.

Defining migraine days, based on longitudinal E-diary data.

van der Arend BWH, Verhagen IE, van Leeuwen M, et al.

Cephalalgia : an international journal of headache 2023; (43(5)):3331024231166625 doi:10.1177/03331024231166625.

Evaluating migraine with typical aura with neuroimaging.

Karsan N, Silva E, Goadsby PJ

Frontiers in human neuroscience 2023; (17()):1112790 doi:10.3389/fnhum.2023.1112790.

Assessment of the Prevalence and Level of Awareness of Medication Overuse Headache Among the General Population in Makkah City, Saudi Arabia.

Alharbi AS, Alharbi OF, Qutub FL, et al.

Cureus 2023; (15(4)):e37985 doi:10.7759/cureus.37985.

Migraine with and without aura in relation to the menstrual cycle and other hormonal milestones: A prospective cohort study.

Verhagen IE, van der Arend BW, van Casteren DS, et al.

Cephalalgia : an international journal of headache 2023; (43(6)):3331024231164322 doi:10.1177/03331024231164322.

A Case of Reversible Posterior Leukoencephalopathy Syndrome (PRES) With a History of Migraine and Onset With Initial Visual Aura and Migraine-Like Headache, With a Significant Response to Lasmiditan: A Case Report.

Sadamoto Y

Cureus 2023; (15(11)):e49311 doi:10.7759/cureus.49311.

Migraine without aura.

Paemeleire K, Vandenbussche N, Stark R

Handbook of clinical neurology 2023; (198()):151-167 doi:10.1016/B978-0-12-823356-6.00007-X.

Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.

Chase BA, Semenov I, Rubin S, et al.

Headache 2024; (64(1)):68-92 doi:10.1111/head.14655.

Neuromodulation in migraine.

Arca KN, Lambru G, Starling AJ

Handbook of clinical neurology 2024; (199()):179-200 doi:10.1016/B978-0-12-823357-3.00003-3.

Psychiatric comorbidities of migraine.

McCracken HT, Thaxter LY, Smitherman TA

Handbook of clinical neurology 2024; (199()):505-516 doi:10.1016/B978-0-12-823357-3.00013-6.

Headache Disorders: Differentiating Primary and Secondary Etiologies.

Hernandez J, Molina E, Rodriguez A, et al.

Journal of integrative neuroscience 2024; (23(2)):43 doi:10.31083/j.jin2302043.

Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.

Charles AC, Digre KB, Goadsby PJ, et al.

Headache 2024; (64(4)):333-341 doi:10.1111/head.14692.

Migraine and Its Treatment from the Medicinal Chemistry Perspective.

Pehlivanlar E, Carradori S, Simsek R

ACS pharmacology & translational science 2024; (7(4)):951-966 doi:10.1021/acsptsci.3c00370.

Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review.

Naghdi S, Underwood M, Brown A, et al.

BMJ neurology open 2024; (6(1)):e000616 doi:10.1136/bmjno-2023-000616.

Reliability, validity, and responsiveness of the Arabic version of HIT-6 questionnaire in patients with migraine indicated for preventive therapy: A multi-center study.

Hussein M, Hassan A, Nada MAF, et al.

Headache 2024; (64(5)):500-508 doi:10.1111/head.14719.

Prevalence of cranial autonomic symptoms in frequent episodic tension-type headache: A post hoc analysis of the cross-sectional Migraine in Poland study.

Straburzyński M, Waliszewska-Prosół M, Nowaczewska M, et al.

Dental and medical problems 2024; (61(4)):489-493 doi:10.17219/dmp/175611.

Predictive performance of the common red flags in emergency department headache patients: a HEAD and HEAD-Colombia study.

Chu K, Kelly AM, Kuan WS, et al.

Emergency medicine journal : EMJ 2024; (41(6)):368-375 doi:10.1136/emermed-2023-213461.

[Non-medical Approaches to Headache Prevention: What is the Evidence?]

Schäfer B

Fortschritte der Neurologie-Psychiatrie 2024; (92(7-08)):294-297 doi:10.1055/a-2318-8941.

Preserved working memory performance along with subcortical modulation during peri-ictal phases in spontaneous migraine attacks.

Ruiz-Tagle A, Caetano G, Fouto A, et al.

Headache 2025; (65(3)):407-419 doi:10.1111/head.14850.

Migraine treatment: Position paper of the French Headache Society.

Moisset X, Demarquay G, de Gaalon S, et al.

Revue neurologique 2024; (180(10)):1087-1099 doi:10.1016/j.neurol.2024.09.008.

A critical appraisal of the International Classification of Headache Disorders migraine diagnostic criteria based on a retrospective multicenter cross-sectional headache registry study in youth.

Patterson Gentile C, Hershey AD, Szperka CL

Headache 2024; (64(10)):1217-1229 doi:10.1111/head.14858.

2023 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for the Management of Headache.

Sico JJ, Antonovich NM, Ballard-Hernandez J, et al.

Annals of internal medicine 2024; (177(12)):1675-1694 doi:10.7326/ANNALS-24-00551.

Neuromodulation for Headache Management in Pregnancy.

Smirnoff L, Bravo M, Hyppolite T

Current pain and headache reports 2025; (29(1)):14 doi:10.1007/s11916-024-01344-1.

Comparative Effectiveness of Pharmacologic Treatments for the Prevention of Episodic Migraine Headache: A Systematic Review and Network Meta-analysis for the American College of Physicians.

Damen JAA, Yang B, Idema DL, et al.

Annals of internal medicine 2025; (178(3)):369-380 doi:10.7326/ANNALS-24-00315.

Behavioral interventions for migraine prevention: A systematic review and meta-analysis.

Treadwell JR, Tsou AY, Rouse B, et al.

Headache 2025; (65(4)):668-694 doi:10.1111/head.14914.

Migraine with and without aura-two distinct entities? A narrative review.

Grodzka O, Dzagoevi K, Rees T, et al.

The journal of headache and pain 2025; (26(1)):77 doi:10.1186/s10194-025-01998-1.

Neuroimaging of patients with headache in the pediatric emergency department: A single center retrospective study.

Shin D, Lee YJ, Jo YH, et al.

Pediatrics and neonatology 2026; (67(1)):7-12 doi:10.1016/j.pedneo.2024.11.008.

[Education for medication overuse headache : Results of a systematic literature review].

Diener HC, Graf M, Löhr H, Kropp P

Schmerz (Berlin, Germany) 2025; doi:10.1007/s00482-025-00891-9.

Patient Adherence and Long-Term Tolerability of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Migraine Prevention: A Systematic Review.

Ray R, Virk GS, Regmi N, et al.

Cureus 2025; (17(8)):e91347 doi:10.7759/cureus.91347.

Impact of fasting during Ramadan on migraine in the Algerian population.

Goufa E, Chentouf A, Belabbas S, Boughrara W

Neurologia 2025; (40(8)):762-767 doi:10.1016/j.nrleng.2025.09.010.

International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraine.

Yuan H, Orr SL, Al-Karagholi MAM, et al.

Cephalalgia : an international journal of headache 2025; (45(10)):3331024251388377 doi:10.1177/03331024251388377.

A Prospective Multicenter Study on the Evaluation of Frequency of Idiopathic Intracranial Hypertension in Korea.

Kim BS, Cho SJ, Cho KH, et al.

Journal of Korean medical science 2025; (40(41)):e278 doi:10.3346/jkms.2025.40.e278.

Characteristics and management of headache among psychiatric outpatients at a Japanese general hospital: A retrospective study with an exploratory CGRP case series.

Otani K, Imbe N, Shindo R

PCN reports : psychiatry and clinical neurosciences 2025; (4(4)):e70235 doi:10.1002/pcn5.70235.

Drugs for Migraine Prophylaxis.

Diener HC, Grans J, Reuter U

Deutsches Arzteblatt international 2026; (123(5)):119-126.

Investigation of the rimegepant effect on cerebral and extracerebral arteries during migraine attacks: a longitudinal magnetic resonance angiography study.

Chaudhry BA, Younis S, Al-Mashat H, et al.

Brain communications 2026; (8(1)):fcag004 doi:10.1093/braincomms/fcag004.

Integrating gepants into clinical practice for the acute treatment of migraine.

Lipton RB, Dodick DW, Davis L, et al.

Headache 2026; (66(4)):976-989 doi:10.1111/head.70047.

Migraine across the menopausal transition and beyond: A narrative review.

Korn TF, Bernstein C

Headache 2026; (66(6)):1390-1404 doi:10.1111/head.70071.

Clinical Predictors of Intracranial Pathology in Emergency Department Patients with Non-traumatic Headache and No Neurological Deficits: Prospective Study.

Serinken M, Eken C, Güngör F, et al.

The western journal of emergency medicine 2026; (27(2)):298-303 doi:10.5811/westjem.48670.

Environmental and psychological risk factors for migraine chronification in China: A multicenter prospective cohort study.

Ma L, Liu L, Ran Y, et al.

Cephalalgia : an international journal of headache 2026; (46(5)):3331024261446614 doi:10.1177/03331024261446614.

Rimegepant for the acute treatment of migraine: a systematic review and meta-analysis.

Istoc M, Chaudhry BA, Christensen RH, et al.

The journal of headache and pain 2026; (27(1)).

Deficient inhibition of irrelevant visual information in migraine: A magnetoencephalography study of alpha-band activity.

Masson R, ElShafei A, Demarquay G, et al.

Headache 2026; (66(7)):1459-1473 doi:10.1111/head.70108.

Headache psychiatry: A structured narrative review and integrative framework.

Otani K

PCN reports : psychiatry and clinical neurosciences 2026; (5(2)):e70347 doi:10.1002/pcn5.70347.

Evaluating the relationship between the 4-item migraine interictal burden scale and other patient-reported outcome measures: a post hoc analysis from a phase 3 migraine prevention study.

Lampl C, Lipton RB, Lipsius S, et al.

Frontiers in neurology 2026; (17()):1808619 doi:10.3389/fneur.2026.1808619.